Climb Bio Inc.

CLYM | NASDAQ

Price Alert Chart Builder DCF Calculator

$10.24

-$0.09 (-0.87%)

At close: Oct 30, 2026, 3:59 PM ET

$10.25

+$0.01 (+0.10%)

Pre-market: Nov 2, 2026, 4:36 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.87%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

27.5

+2.0 pts

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #850/1028 (Top 83%)

Full Analysis

Key Statistics

Market Data

Market Cap $588.15M

1D Range

10.02 10.52

52W Range

1.64 17.84

Valuation (TTM)

PE -12.34

PB 2.46

EV/EBITDA -6.85

Valuation (NTM)

Forward PE N/A

Forward PEG 4.10

Price Target $28.00

Cash Flow

FCF Yield -9.0%

SBC Adj. FCF Yield -10.4%

SBC Impact -15.3%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 53.8% | 24.2%

FCF 3Y | 5Y -85.9% | -5.4%

Returns

ROA -23.4%

ROE -31.8%

ROIC -26.9%

Financial Health

Net Cash

$183.12M

Current Ratio 31.45

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an an...

Sector Healthcare

Industry Biotechnology

Employees 28

IPO Date Aug 10, 2021

Website climbbio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$26.50

Upside

+158.79%

Buy (7)

Hold (0)

Sell (0)

Analyst Details ➞